Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Radiation Dose-Escalation Study of Intensity-Modulated Radiotherapy (IMRT) With Concurrent Gemcitabine in Patients With Unresectable Pancreatic Cancer

NCT00593866 is registered in ClinicalTrials.gov with University of Michigan Rogel Cancer Center as lead sponsor.

NCT NCT00593866
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00593866 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Radiation Dose-Escalation Study of Intensity-Modulated Radiotherapy (IMRT) With Concurrent Gemcitabine in Patients With Unresectable Pancreatic Cancer
Lead sponsor
University of Michigan Rogel Cancer Center
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2006
Completion date
October 31, 2014
Enrollment
50 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer